Retas Skyclavs was one of the biggest in 2023 for $7.3bn US by Biogen rare disease drug estimate 5,000 patients in US and $1.5bn sales 2030….. premium was only 60% on their share price at the time.
2591 ‘s potential patients with only current x 4 indications is x 10 (as per presentations) that of Skyclavs with scope for many more potentially…..
Retas deal x 10 is $10-15bn in sales 2030-2033 US only for the potential future of 2591 as a starting point. Likely $30 bn globally…
Fairly attractive asset.
- Forums
- ASX - By Stock
- The NDD box seat
Retas Skyclavs was one of the biggest in 2023 for $7.3bn US by...
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.62 |
Change
-0.240(1.15%) |
Mkt cap ! $2.635B |
Open | High | Low | Value | Volume |
$20.45 | $20.62 | $20.26 | $4.698M | 229.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 221 | $20.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.62 | 1553 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 221 | 20.600 |
1 | 10 | 20.560 |
3 | 1119 | 20.550 |
1 | 665 | 20.510 |
1 | 193 | 20.500 |
Price($) | Vol. | No. |
---|---|---|
20.620 | 1553 | 1 |
20.670 | 1121 | 1 |
20.680 | 1084 | 2 |
20.690 | 1000 | 1 |
20.700 | 483 | 1 |
Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |